RO7269162
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for RO7269162, covering 2025-02-25 to 2026-02-18. Get the full timeline:
Most recent: Clinical Trial Update: A Study to Evaluate the Safety and Biomarker Effects of RO7269162 in Participants at Risk for or at the Prodromal Stage of Alzheimer's Disease (AD) [Phase 2]